{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T14:39:23Z","timestamp":1793716763904,"version":"4.6.1"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2023,7,15]],"date-time":"2023-07-15T00:00:00Z","timestamp":1689379200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,7,15]],"date-time":"2023-07-15T00:00:00Z","timestamp":1689379200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Deutsches Krebsforschungszentrum (DKFZ)"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2023,10]]},"abstract":"<jats:title>Abstract\n<\/jats:title><jats:sec>\n                <jats:title>Aim<\/jats:title>\n                <jats:p>The development of biomarkers that can reliably and early predict response to immune checkpoint inhibitors (ICIs) is crucial in melanoma. In recent years, the gut microbiome has emerged as an important regulator of immunotherapy response, which may, moreover, serve as a surrogate marker and prognosticator in oncological patients under immunotherapy. Aim of the present study is to investigate if physiologic colonic [<jats:sup>18<\/jats:sup>F]FDG uptake in PET\/CT before start of ICIs correlates with clinical outcome of metastatic melanoma patients. The relation between [<jats:sup>18<\/jats:sup>F]FDG uptake in lymphoid cell-rich organs and long-term patient outcome is also assessed.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methodology<\/jats:title>\n                <jats:p>One hundred nineteen stage IV melanoma patients scheduled for immunotherapy with ipilimumab, applied either as monotherapy or in combination with nivolumab, underwent baseline [<jats:sup>18<\/jats:sup>F]FDG PET\/CT. PET\/CT data analysis consisted of standardized uptake value (SUV), metabolic tumor volume (MTV), and total lesion glycolysis (TLG) calculations in the colon as well as measurements of the colon-to-liver SUV ratios (CLR<jats:sub>mean<\/jats:sub>, CLR<jats:sub>max<\/jats:sub>). Visual grading of colon uptake based on a four-point scale was also performed. Moreover, the spleen-to-liver SUV ratios (SLR<jats:sub>mean<\/jats:sub>, SLR<jats:sub>max<\/jats:sub>) and the bone marrow-to-liver SUV ratios (BLR<jats:sub>mean<\/jats:sub>, BLR<jats:sub>max<\/jats:sub>) were calculated. We also measured serum lipopolysaccharide (LPS) levels as a marker for bacterial translocation and surrogate for mucosal defense homeostasis. The results were correlated with patients\u2019 best clinical response, progression-free survival (PFS), and overall survival (OS) as well as clinical signs of colitis.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Median follow-up [95%CI] from the beginning of immunotherapy was 64.6\u00a0months [61.0\u201368.6\u00a0months]. Best response to treatment was progressive disease (PD) for 60 patients, stable disease (SD) for 37 patients, partial response (PR) for 18 patients, and complete response (CR) for 4 patients. Kaplan\u2013Meier curves demonstrated a trend for longer PFS and OS in patients with lower colonic SUV and CLR values; however, no statistical significance for these parameters as prognostic factors was demonstrated. On the other hand, patients showing disease control as best response to treatment (SD, PR, CR) had significantly lower colonic MTV and TLG than those showing PD. With regard to lymphoid cell-rich organs, significantly lower baseline SLR<jats:sub>max<\/jats:sub> and BLR<jats:sub>max<\/jats:sub> were observed in patients responding with disease control than progression to treatment. Furthermore, patients with lower SLR<jats:sub>max<\/jats:sub> and BLR<jats:sub>max<\/jats:sub> values had a significantly longer OS when dichotomized at their median. In multivariate analysis, PET parameters that were found to significantly adversely correlate with patient survival were colonic MTV for PFS, colonic TLG for PFS, and BLR<jats:sub>max<\/jats:sub> for PFS and OS.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Physiologic colonic [<jats:sup>18<\/jats:sup>F]FDG uptake in PET\/CT, as assessed by means of SUV, before start of ipilimumab-based treatment does not seem to independently predict patient survival of metastatic melanoma. On the other hand, volumetric PET parameters, such as MTV and TLG, derived from the normal gut may identify patients showing disease control to immunotherapy and significantly correlate with PFS. Moreover, the investigation of glucose metabolism in the spleen and the bone marrow may offer prognostic information.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00259-023-06327-9","type":"journal-article","created":{"date-parts":[[2023,7,15]],"date-time":"2023-07-15T08:02:06Z","timestamp":1689408126000},"page":"3709-3722","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Can physiologic colonic [18F]FDG uptake in PET\/CT imaging predict response to immunotherapy in metastatic melanoma?"],"prefix":"10.1007","volume":"50","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8739-8741","authenticated-orcid":false,"given":"Christos","family":"Sachpekidis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph K.","family":"Stein-Thoeringer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annette","family":"Kopp-Schneider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivienn","family":"Weru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonia","family":"Dimitrakopoulou-Strauss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica C.","family":"Hassel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,7,15]]},"reference":[{"issue":"10304","key":"6327_CR1","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1016\/S0140-6736(21)01206-X","volume":"398","author":"MS Carlino","year":"2021","unstructured":"Carlino MS, Larkin J, Long GV. Immune checkpoint inhibitors in melanoma. Lancet. 2021;398(10304):1002\u201314. https:\/\/doi.org\/10.1016\/S0140-6736(21)01206-X.","journal-title":"Lancet."},{"issue":"4","key":"6327_CR2","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1053\/j.seminoncol.2015.05.003","volume":"42","author":"D Pardoll","year":"2015","unstructured":"Pardoll D. Cancer and the immune system: Basic concepts and targets for intervention. Semin Oncol. 2015;42(4):523\u201338. https:\/\/doi.org\/10.1053\/j.seminoncol.2015.05.003.","journal-title":"Semin Oncol."},{"issue":"4","key":"6327_CR3","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1056\/NEJMoa1412082","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015;372(4):320\u201330.","journal-title":"N Engl J Med."},{"issue":"26","key":"6327_CR4","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert C, Schachter J, Long GV, Arance A, Grob JJ, et al. Pembrolizumab versus Ipilimumab in advanced melanoma. N Engl J Med. 2015;372(26):2521\u201332.","journal-title":"N Engl J Med."},{"issue":"1","key":"6327_CR5","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1056\/NEJMoa1504030","volume":"373","author":"J Larkin","year":"2015","unstructured":"Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, et al. combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373(1):23\u201334.","journal-title":"N Engl J Med."},{"key":"6327_CR6","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1003466","volume":"363","author":"FS Hodi","year":"2010","unstructured":"Hodi FS, O\u2019Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:711\u201323.","journal-title":"N Engl J Med."},{"issue":"1","key":"6327_CR7","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1056\/NEJMoa2109970","volume":"386","author":"HA Tawbi","year":"2022","unstructured":"Tawbi HA, Schadendorf D, Lipson EJ, Ascierto PA, Matamala L, Castillo Guti\u00e9rrez E, et al. RELATIVITY-047 investigators. relatlimab and nivolumab versus nivolumab in untreated advanced melanoma. N Engl J Med. 2022;386(1):24\u201334. https:\/\/doi.org\/10.1056\/NEJMoa2109970.","journal-title":"N Engl J Med."},{"issue":"4","key":"6327_CR8","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.cell.2017.01.017","volume":"168","author":"P Sharma","year":"2017","unstructured":"Sharma P, Hu-Lieskovan S, Wargo JA, Ribas A. Primary, adaptive, and acquired resistance to cancer immunotherapy. Cell. 2017;168(4):707\u201323. https:\/\/doi.org\/10.1016\/j.cell.2017.01.017.","journal-title":"Cell."},{"key":"6327_CR9","doi-asserted-by":"publisher","first-page":"371","DOI":"10.3390\/cancers12020371","volume":"12","author":"P Decazes","year":"2020","unstructured":"Decazes P, Bohn P. Immunotherapy by immune checkpoint inhibitors and nuclear medicine imaging: current and future applications. Cancers (Basel). 2020;12:371. https:\/\/doi.org\/10.3390\/cancers12020371.","journal-title":"Cancers (Basel)."},{"issue":"2","key":"6327_CR10","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1148\/radiol.212481","volume":"304","author":"DJ Hughes","year":"2022","unstructured":"Hughes DJ, Subesinghe M, Taylor B, Bille A, Spicer J, Papa S, et al. 18F FDG PET\/CT and novel molecular imaging for directing immunotherapy in cancer. Radiology. 2022;304(2):246\u201364. https:\/\/doi.org\/10.1148\/radiol.212481.","journal-title":"Radiology."},{"issue":"2","key":"6327_CR11","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1056\/NEJMra1703481","volume":"378","author":"MA Postow","year":"2018","unstructured":"Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med. 2018;378(2):158\u201368.","journal-title":"N Engl J Med."},{"issue":"1","key":"6327_CR12","doi-asserted-by":"publisher","first-page":"43","DOI":"10.3390\/cancers13010043","volume":"13","author":"A Koulouridi","year":"2020","unstructured":"Koulouridi A, Messaritakis I, Gouvas N, Tsiaoussis J, Souglakos J. Immunotherapy in solid tumors and gut microbiota: the correlation-a special reference to colorectal cancer. Cancers (Basel). 2020;13(1):43. https:\/\/doi.org\/10.3390\/cancers13010043.","journal-title":"Cancers (Basel)."},{"issue":"6264","key":"6327_CR13","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1126\/science.aac4255","volume":"350","author":"A Sivan","year":"2015","unstructured":"Sivan A, Corrales L, Hubert N, Williams JB, Aquino-Michaels K, Earley ZM, et al. Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy. Science. 2015;350(6264):1084\u20139.","journal-title":"Science."},{"issue":"6264","key":"6327_CR14","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1126\/science.aad1329","volume":"350","author":"M V\u00e9tizou","year":"2015","unstructured":"V\u00e9tizou M, Pitt JM, Daill\u00e8re R, Lepage P, Waldschmitt N, Flament C, et al. Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. Science. 2015;350(6264):1079\u201384. https:\/\/doi.org\/10.1126\/science.aad1329.","journal-title":"Science."},{"issue":"6371","key":"6327_CR15","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1126\/science.aan3706","volume":"359","author":"B Routy","year":"2018","unstructured":"Routy B, Le Chatelier E, Derosa L, Duong CPM, Alou MT, Daill\u00e8re R, et al. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science. 2018;359(6371):91\u20137. https:\/\/doi.org\/10.1126\/science.aan3706.","journal-title":"Science."},{"issue":"6371","key":"6327_CR16","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1126\/science.aan4236","volume":"359","author":"V Gopalakrishnan","year":"2018","unstructured":"Gopalakrishnan V, Spencer CN, Nezi L, Reuben A, Andrews MC, Karpinets TV, et al. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science. 2018;359(6371):97\u2013103. https:\/\/doi.org\/10.1126\/science.aan4236.","journal-title":"Science."},{"key":"6327_CR17","doi-asserted-by":"publisher","unstructured":"Simpson RC, Shanahan ER, Batten M, Reijers ILM, Read M, Silva IP, et al. Diet-driven microbial ecology underpins associations between cancer immunotherapy outcomes and the gut microbiome. Nat Med. 2022; https:\/\/doi.org\/10.1038\/s41591-022-01965-2.","DOI":"10.1038\/s41591-022-01965-2"},{"issue":"6","key":"6327_CR18","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1093\/annonc\/mdx108","volume":"28","author":"N Chaput","year":"2017","unstructured":"Chaput N, Lepage P, Coutzac C, Soularue E, Le Roux K, Monot C, et al. Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab. Ann Oncol. 2017;28(6):1368\u201379. https:\/\/doi.org\/10.1093\/annonc\/mdx108.","journal-title":"Ann Oncol."},{"issue":"81","key":"6327_CR19","doi-asserted-by":"publisher","first-page":"eabo2003","DOI":"10.1126\/sciimmunol.abo2003","volume":"8","author":"Y Choi","year":"2023","unstructured":"Choi Y, Lichterman JN, Coughlin LA, Poulides N, Li W, Del Valle P, et al. Immune checkpoint blockade induces gut microbiota translocation that augments extraintestinal antitumor immunity. Sci Immunol. 2023;8(81):eabo2003. https:\/\/doi.org\/10.1126\/sciimmunol.abo2003.","journal-title":"Sci Immunol"},{"issue":"12","key":"6327_CR20","doi-asserted-by":"publisher","first-page":"175628481987091","DOI":"10.1177\/1756284819870911","volume":"16","author":"RC Pezo","year":"2019","unstructured":"Pezo RC, Wong M, Martin A. Impact of the gut microbiota on immune checkpoint inhibitor-associated toxicities. Therap Adv Gastroenterol. 2019;16(12):1756284819870911. https:\/\/doi.org\/10.1177\/1756284819870911.","journal-title":"Therap Adv Gastroenterol."},{"key":"6327_CR21","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1093\/jnci\/djq455","volume":"103","author":"Y Xing","year":"2011","unstructured":"Xing Y, Bronstein Y, Ross MI, et al. Contemporary diagnostic imaging modalities for the staging and surveillance of melanoma patients: a metaanalysis. J Natl Cancer Inst. 2011;103:129\u201342.","journal-title":"J Natl Cancer Inst."},{"key":"6327_CR22","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1007\/s00259-015-3187-2","volume":"43","author":"SC Sch\u00fcle","year":"2016","unstructured":"Sch\u00fcle SC, Eigentler TK, Garbe C, la Foug\u00e8re C, Nikolaou K, Pfannenberg C. Influence of (18)F-FDG PET\/CT on therapy management in patients with stage III\/IV malignant melanoma. Eur J Nucl Med Mol Imaging. 2016;43:482\u20138.","journal-title":"Eur J Nucl Med Mol Imaging."},{"issue":"5","key":"6327_CR23","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1007\/s00262-018-2229-6","volume":"68","author":"A Dimitrakopoulou-Strauss","year":"2019","unstructured":"Dimitrakopoulou-Strauss A. Monitoring of patients with metastatic melanoma treated with immune checkpoint inhibitors using PET-CT. Cancer Immunol Immunother. 2019;68(5):813\u201322. https:\/\/doi.org\/10.1007\/s00262-018-2229-6.","journal-title":"Cancer Immunol Immunother."},{"key":"6327_CR24","volume-title":"Atlas of Response to Immunotherapy","author":"C Sachpekidis","year":"2020","unstructured":"Sachpekidis C, Dimitrakopoulou-Strauss A. Melanoma: 18F-FDG PET\/CT for response assessment of melanoma following immunotherapy. In: Lopci E, Fanti S, editors. Atlas of Response to Immunotherapy. Cham: Springer; 2020."},{"issue":"2","key":"6327_CR25","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1007\/s00259-020-04967-9","volume":"48","author":"N Ayati","year":"2021","unstructured":"Ayati N, Sadeghi R, Kiamanesh Z, Lee ST, Zakavi SR, Scott AM. The value of 18F-FDG PET\/CT for predicting or monitoring immunotherapy response in patients with metastatic melanoma: a systematic review and meta-analysis. Eur J Nucl Med Mol Imaging. 2021;48(2):428\u201348. https:\/\/doi.org\/10.1007\/s00259-020-04967-9.","journal-title":"Eur J Nucl Med Mol Imaging."},{"issue":"7","key":"6327_CR26","doi-asserted-by":"publisher","first-page":"2323","DOI":"10.1007\/s00259-022-05780-2","volume":"49","author":"E Lopci","year":"2022","unstructured":"Lopci E, Hicks RJ, Dimitrakopoulou-Strauss A, Dercle L, Iravani A, Seban RD, et al. Joint EANM\/SNMMI\/ANZSNM practice guidelines\/procedure standards on recommended use of [18F]FDG PET\/CT imaging during immunomodulatory treatments in patients with solid tumors version 1.0. Eur J Nucl Med Mol Imaging. 2022;49(7):2323\u201341. https:\/\/doi.org\/10.1007\/s00259-022-05780-2.","journal-title":"Eur J Nucl Med Mol Imaging."},{"issue":"3","key":"6327_CR27","doi-asserted-by":"publisher","first-page":"878","DOI":"10.3390\/cancers15030878","volume":"15","author":"L Evangelista","year":"2023","unstructured":"Evangelista L, Bianchi A, Annovazzi A, Sciuto R, Di Traglia S, Bauckneht M, et al. ITA-IMMUNO-PET: The Role of [18F]FDG PET\/CT for Assessing Response to Immunotherapy in Patients with Some Solid Tumors. Cancers. 2023;15(3):878. https:\/\/doi.org\/10.3390\/cancers15030878.","journal-title":"Cancers."},{"issue":"8","key":"6327_CR28","doi-asserted-by":"publisher","first-page":"667","DOI":"10.2217\/imt-2018-0146","volume":"11","author":"N Lang","year":"2019","unstructured":"Lang N, Dick J, Slynko A, Schulz C, Dimitrakopoulou-Strauss A, Sachpekidis C, et al. Clinical significance of signs of autoimmune colitis in 18F-fluorodeoxyglucose positron emission tomography-computed tomography of 100 stage-IV melanoma patients. Immunotherapy. 2019;11(8):667\u201376. https:\/\/doi.org\/10.2217\/imt-2018-0146.","journal-title":"Immunotherapy."},{"issue":"3","key":"6327_CR29","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1097\/CMR.0000000000000566","volume":"29","author":"B Boursi","year":"2019","unstructured":"Boursi B, Werner TJ, Gholami S, Margalit O, Baruch E, Markel G, et al. Physiologic colonic fluorine-18-fluorodeoxyglucose uptake may predict response to immunotherapy in patients with metastatic melanoma. Melanoma Res. 2019;29(3):318\u201321. https:\/\/doi.org\/10.1097\/CMR.0000000000000566.","journal-title":"Melanoma Res."},{"issue":"8","key":"6327_CR30","doi-asserted-by":"publisher","first-page":"2573","DOI":"10.1007\/s00259-020-05103-3","volume":"48","author":"K Prigent","year":"2021","unstructured":"Prigent K, Lasnon C, Ezine E, Janson M, Coudrais N, Joly E, et al. Assessing immune organs on 18F-FDG PET\/CT imaging for therapy monitoring of immune checkpoint inhibitors: inter-observer variability, prognostic value and evolution during the treatment course of melanoma patients. Eur J Nucl Med Mol Imaging. 2021;48(8):2573\u201385. https:\/\/doi.org\/10.1007\/s00259-020-05103-3.","journal-title":"Eur J Nucl Med Mol Imaging."},{"issue":"3","key":"6327_CR31","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1007\/s00259-017-3870-6","volume":"45","author":"H Anwar","year":"2018","unstructured":"Anwar H, Sachpekidis C, Winkler J, Kopp-Schneider A, Haberkorn U, Hassel JC, Dimitrakopoulou-Strauss A. Absolute number of new lesions on 18F-FDG PET\/CT is more predictive of clinical response than SUV changes in metastatic melanoma patients receiving ipilimumab. Eur J Nucl Med Mol Imaging. 2018;45(3):376\u201383. https:\/\/doi.org\/10.1007\/s00259-017-3870-6.","journal-title":"Eur J Nucl Med Mol Imaging."},{"issue":"10","key":"6327_CR32","doi-asserted-by":"publisher","first-page":"2301","DOI":"10.1007\/s00259-020-04757-3","volume":"47","author":"RD Seban","year":"2020","unstructured":"Seban RD, Moya-Plana A, Antonios L, Yeh R, Marabelle A, Deutsch E, et al. Prognostic 18F-FDG PET biomarkers in metastatic mucosal and cutaneous melanoma treated with immune checkpoint inhibitors targeting PD-1 and CTLA-4. Eur J Nucl Med Mol Imaging. 2020;47(10):2301\u201312. https:\/\/doi.org\/10.1007\/s00259-020-04757-3.","journal-title":"Eur J Nucl Med Mol Imaging."},{"issue":"3","key":"6327_CR33","doi-asserted-by":"publisher","first-page":"335","DOI":"10.2967\/jnumed.118.213652","volume":"60","author":"K Ito","year":"2019","unstructured":"Ito K, Teng R, Sch\u00f6der H, Humm JL, Ni A, Michaud L, et al. 18F-FDG PET\/CT for Monitoring of Ipilimumab Therapy in Patients with Metastatic Melanoma. J Nucl Med. 2019;60(3):335\u201341. https:\/\/doi.org\/10.2967\/jnumed.118.213652.","journal-title":"J Nucl Med."},{"issue":"4","key":"6327_CR34","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1007\/s00259-018-4211-0","volume":"46","author":"K Ito","year":"2019","unstructured":"Ito K, Sch\u00f6der H, Teng R, Humm JL, Ni A, Wolchok JD, Weber WA. Prognostic value of baseline metabolic tumor volume measured on 18F-fluorodeoxyglucose positron emission tomography\/computed tomography in melanoma patients treated with ipilimumab therapy. Eur J Nucl Med Mol Imaging. 2019;46(4):930\u20139. https:\/\/doi.org\/10.1007\/s00259-018-4211-0.","journal-title":"Eur J Nucl Med Mol Imaging."},{"issue":"11","key":"6327_CR35","doi-asserted-by":"publisher","first-page":"2298","DOI":"10.1007\/s00259-019-04411-7","volume":"46","author":"RD Seban","year":"2019","unstructured":"Seban RD, Nemer JS, Marabelle A, Yeh R, Deutsch E, Ammari S, et al. Prognostic and theranostic 18F-FDG PET biomarkers for anti-PD1 immunotherapy in metastatic melanoma: association with outcome and transcriptomics. Eur J Nucl Med Mol Imaging. 2019;46(11):2298\u2013310. https:\/\/doi.org\/10.1007\/s00259-019-04411-7.","journal-title":"Eur J Nucl Med Mol Imaging."},{"issue":"12","key":"6327_CR36","doi-asserted-by":"publisher","first-page":"2776","DOI":"10.1007\/s00259-020-04815-w","volume":"47","author":"A Iravani","year":"2020","unstructured":"Iravani A, Osman MM, Weppler AM, Wallace R, Galligan A, Lasocki A, et al. FDG PET\/CT for tumoral and systemic immune response monitoring of advanced melanoma during first-line combination ipilimumab and nivolumab treatment. Eur J Nucl Med Mol Imaging. 2020;47(12):2776\u201386. https:\/\/doi.org\/10.1007\/s00259-020-04815-w.","journal-title":"Eur J Nucl Med Mol Imaging."},{"issue":"12","key":"6327_CR37","doi-asserted-by":"publisher","first-page":"2787","DOI":"10.1007\/s00259-020-04792-0","volume":"47","author":"R Nakamoto","year":"2020","unstructured":"Nakamoto R, Zaba LC, Rosenberg J, Reddy SA, Nobashi TW, Davidzon G, et al. Prognostic value of volumetric PET parameters at early response evaluation in melanoma patients treated with immunotherapy. Eur J Nucl Med Mol Imaging. 2020;47(12):2787\u201395. https:\/\/doi.org\/10.1007\/s00259-020-04792-0.","journal-title":"Eur J Nucl Med Mol Imaging."},{"issue":"2","key":"6327_CR38","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1007\/s00262-018-2279-9","volume":"68","author":"C Sachpekidis","year":"2019","unstructured":"Sachpekidis C, Larrib\u00e8re L, Kopp-Schneider A, Hassel JC, Dimitrakopoulou-Strauss A. Can benign lymphoid tissue changes in 18F-FDG PET\/CT predict response to immunotherapy in metastatic melanoma? Cancer Immunol Immunother. 2019;68(2):297\u2013303. https:\/\/doi.org\/10.1007\/s00262-018-2279-9.","journal-title":"Cancer Immunol Immunother."},{"issue":"4","key":"6327_CR39","doi-asserted-by":"publisher","first-page":"e272","DOI":"10.1097\/RLU.0000000000002453","volume":"44","author":"T Nobashi","year":"2019","unstructured":"Nobashi T, Baratto L, Reddy SA, Srinivas S, Toriihara A, Hatami N, et al. Predicting response to immunotherapy by evaluating tumors, lymphoid cell-rich organs, and immune-related adverse events using FDG-PET\/CT. Clin Nucl Med. 2019;44(4):e272\u20139. https:\/\/doi.org\/10.1097\/RLU.0000000000002453.","journal-title":"Clin Nucl Med."},{"issue":"6","key":"6327_CR40","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.1007\/s00259-021-05650-3","volume":"49","author":"N Hribernik","year":"2022","unstructured":"Hribernik N, Huff DT, Studen A, Zevnik K, Klane\u010dek \u017d, Emamekhoo H, et al. Quantitative imaging biomarkers of immune-related adverse events in immune-checkpoint blockade-treated metastatic melanoma patients: a pilot study. Eur J Nucl Med Mol Imaging. 2022;49(6):1857\u201369. https:\/\/doi.org\/10.1007\/s00259-021-05650-3.","journal-title":"Eur J Nucl Med Mol Imaging."},{"issue":"3","key":"6327_CR41","doi-asserted-by":"publisher","first-page":"245","DOI":"10.23736\/S1824-4785.22.03453-7","volume":"66","author":"C Sachpekidis","year":"2022","unstructured":"Sachpekidis C, Hassel JC, Dimitrakopoulou-Strauss A. Adverse effects under immune checkpoint inhibitors on [18F]FDG PET\/CT imaging. Q J Nucl Med Mol Imaging. 2022;66(3):245\u201354. https:\/\/doi.org\/10.23736\/S1824-4785.22.03453-7.","journal-title":"Q J Nucl Med Mol Imaging."},{"issue":"1","key":"6327_CR42","doi-asserted-by":"publisher","first-page":"18273","DOI":"10.1038\/s41598-019-54680-3","volume":"9","author":"HJ Yoon","year":"2019","unstructured":"Yoon HJ, Kim HN, Bang JI, Lim W, Moon BI, Paik NS, et al. Physiologic intestinal 18F-FDG uptake is associated with alteration of gut microbiota and proinflammatory cytokine levels in breast cancer. Sci Rep. 2019;9(1):18273. https:\/\/doi.org\/10.1038\/s41598-019-54680-3.","journal-title":"Sci Rep."},{"issue":"2","key":"6327_CR43","doi-asserted-by":"publisher","first-page":"99","DOI":"10.2478\/raon-2013-0035","volume":"48","author":"G Treglia","year":"2014","unstructured":"Treglia G, Taralli S, Salsano M, Muoio B, Sadeghi R, Giovanella L. Prevalence and malignancy risk of focal colorectal incidental uptake detected by (18)F-FDG-PET or PET\/CT: a meta-analysis. Radiol Oncol. 2014;48(2):99\u2013104. https:\/\/doi.org\/10.2478\/raon-2013-0035.","journal-title":"Radiol Oncol."},{"issue":"5","key":"6327_CR44","doi-asserted-by":"publisher","first-page":"W586","DOI":"10.2214\/AJR.14.12817","volume":"204","author":"C Keyzer","year":"2015","unstructured":"Keyzer C, Dhaene B, Blocklet D, De Maertelaer V, Goldman S, Gevenois PA. Colonoscopic findings in patients with incidental colonic focal FDG uptake. AJR Am J Roentgenol. 2015;204(5):W586\u201391. https:\/\/doi.org\/10.2214\/AJR.14.12817.","journal-title":"AJR Am J Roentgenol."},{"issue":"1","key":"6327_CR45","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1007\/s00259-007-0563-6","volume":"35","author":"E Gontier","year":"2008","unstructured":"Gontier E, Fourme E, Wartski M, Blondet C, Bonardel G, Le Stanc E, et al. High and typical 18F-FDG bowel uptake in patients treated with metformin. Eur J Nucl Med Mol Imaging. 2008;35(1):95\u20139. https:\/\/doi.org\/10.1007\/s00259-007-0563-6. http:\/\/www.pmod.com\/files\/download\/v31\/doc\/pbas\/4729.htm.","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"6327_CR46","unstructured":"http:\/\/www.pmod.com\/files\/download\/v31\/doc\/pbas\/4729.htm Accessed: December 17, 2022."},{"key":"6327_CR47","unstructured":"National Cancer Institute. Common terminology criteria for adverse events (CTCAE) Version 4.0 [internet]. Available from: https:\/\/www.eortc.be\/services\/doc\/ctc\/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf. [cited 2022, Sep 30]."},{"issue":"5","key":"6327_CR48","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1128\/jcm.27.5.947-951.1989","volume":"27","author":"GK Lindsay","year":"1989","unstructured":"Lindsay GK, Roslansky PF, Novitsky TJ. Single-step, chromogenic Limulus amebocyte lysate assay for endotoxin. J Clin Microbiol. 1989;27(5):947\u201351. https:\/\/doi.org\/10.1128\/jcm.27.5.947-951.1989.","journal-title":"J Clin Microbiol."},{"issue":"12","key":"6327_CR49","doi-asserted-by":"publisher","first-page":"3826","DOI":"10.1128\/JCM.01189-09","volume":"47","author":"JC Hurley","year":"2009","unstructured":"Hurley JC. Diagnosis of endotoxemia with gram-negative bacteremia is bacterial species dependent: a meta-analysis of clinical studies. J Clin Microbiol. 2009;47(12):3826\u201331. https:\/\/doi.org\/10.1128\/JCM.01189-09.","journal-title":"J Clin Microbiol."},{"issue":"9","key":"6327_CR50","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.2337\/dc09-0467","volume":"32","author":"M Nymark","year":"2009","unstructured":"Nymark M, Pussinen PJ, Tuomainen AM, Forsblom C, Groop PH, Lehto M, FinnDiane Study Group. Serum lipopolysaccharide activity is associated with the progression of kidney disease in finnish patients with type 1 diabetes. Diabetes Care. 2009;32(9):1689\u201393. https:\/\/doi.org\/10.2337\/dc09-0467.","journal-title":"Diabetes Care."},{"issue":"2","key":"6327_CR51","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.cpet.2013.10.002","volume":"9","author":"A Kohan","year":"2014","unstructured":"Kohan A, Avril NE. Pelvis: normal variants and benign findings in FDG-PET\/CT imaging. PET Clin. 2014;9(2):185\u201393. https:\/\/doi.org\/10.1016\/j.cpet.2013.10.002.","journal-title":"PET Clin."},{"issue":"10","key":"6327_CR52","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1097\/MNM.0000000000000170","volume":"35","author":"E Franquet","year":"2014","unstructured":"Franquet E, Palmer MR, Gifford AE, Selen DJ, Chen YC, Sedora-Roman N, et al. Rifaximin suppresses background intestinal 18F-FDG uptake on PET\/CT scans. Nucl Med Commun. 2014;35(10):1026\u201331. https:\/\/doi.org\/10.1097\/MNM.0000000000000170.","journal-title":"Nucl Med Commun."},{"issue":"1","key":"6327_CR53","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s13550-017-0318-8","volume":"7","author":"JY Kang","year":"2017","unstructured":"Kang JY, Kim HN, Chang Y, Yun Y, Ryu S, Shin H, Kim HL. Gut microbiota and physiologic bowel 18F-FDG uptake. EJNMMI Res. 2017;7(1):72. https:\/\/doi.org\/10.1186\/s13550-017-0318-8.","journal-title":"EJNMMI Res."},{"issue":"2","key":"6327_CR54","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0192747","volume":"13","author":"B Boursi","year":"2018","unstructured":"Boursi B, Werner TJ, Gholami S, Houshmand S, Mamtani R, Lewis JD, et al. Functional imaging of the interaction between gut microbiota and the human host: A proof-of-concept clinical study evaluating novel use for 18F-FDG PET-CT. PLoS One. 2018;13(2):e0192747. https:\/\/doi.org\/10.1371\/journal.pone.0192747.","journal-title":"PLoS One."},{"key":"6327_CR55","doi-asserted-by":"publisher","first-page":"7412","DOI":"10.1158\/1078-0432.CCR-09-1624","volume":"15","author":"JD Wolchok","year":"2009","unstructured":"Wolchok JD, Hoos A, O'Day S, Weber JS, Hamid O, Lebb\u00e9 C, Maio M, Binder M, Bohnsack O, Nichol G, Humphrey R, Hodi FS. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res. 2009;15:7412\u201320.","journal-title":"Clin Cancer Res."},{"key":"6327_CR56","doi-asserted-by":"publisher","first-page":"2174","DOI":"10.1093\/annonc\/mdt161","volume":"24","author":"JD Wolchok","year":"2013","unstructured":"Wolchok JD, Weber JS, Maio M, Neyns B, Harmankaya K, Chin K, Cykowski L, de Pril V, Humphrey R, Lebb\u00e9 C. Four-year survival rates for patients with metastatic melanoma who received ipilimumab in phase II clinical trials. Ann Oncol. 2013;24:2174\u201380.","journal-title":"Ann Oncol."},{"issue":"4","key":"6327_CR57","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1007\/s00262-014-1652-6","volume":"64","author":"T Hughes","year":"2015","unstructured":"Hughes T, Klairmont M, Broucek J, Iodice G, Basu S, Kaufman HL. The prognostic significance of stable disease following high-dose interleukin-2 (IL-2) treatment in patients with metastatic melanoma and renal cell carcinoma. Cancer Immunol Immunother. 2015;64(4):459\u201365. https:\/\/doi.org\/10.1007\/s00262-014-1652-6.","journal-title":"Cancer Immunol Immunother"},{"issue":"5","key":"6327_CR58","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1007\/s00259-020-05081-6","volume":"48","author":"L Cvetkovic","year":"2021","unstructured":"Cvetkovic L, R\u00e9gis C, Richard C, Derosa L, Leblond A, Malo J, et al. Physiologic colonic uptake of 18F-FDG on PET\/CT is associated with clinical response and gut microbiome composition in patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitors. Eur J Nucl Med Mol Imaging. 2021;48(5):1550\u20139. https:\/\/doi.org\/10.1007\/s00259-020-05081-6.","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"6327_CR59","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s40644-020-00313-2","volume":"20","author":"A Wong","year":"2020","unstructured":"Wong A, Callahan J, Keyaerts M, Neyns B, Mangana J, Aberle S, et al. 18F-FDGPET\/CT based spleen to liver ratio associates with clini\u00accal outcome to ipilimumab in patients with metastatic melanoma. Cancer Imaging. 2020;20:36.","journal-title":"Cancer Imaging"},{"key":"6327_CR60","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s13550-021-00832-4","volume":"11","author":"C Sachpekidis","year":"2021","unstructured":"Sachpekidis C, Kopp-Schneider A, Hassel JC, Dimitrakopoulou-Strauss A. Assessment of early metabolic progression in melanoma pa\u00actients under immunotherapy: an 18F-FDG PET\/CT study. EJNMMI Res. 2021;11:89.","journal-title":"EJNMMI Res"},{"issue":"8","key":"6327_CR61","doi-asserted-by":"publisher","first-page":"2309","DOI":"10.1007\/s00259-020-05126-w","volume":"48","author":"RD Seban","year":"2021","unstructured":"Seban RD, Champion L, Schwartz LH, Dercle L. Spleen glucose metabolism on [18F]-FDG PET\/CT: a dynamic double-edged biomarker predicting outcome in cancer patients. Eur J Nucl Med Mol Imaging. 2021;48(8):2309\u201311. https:\/\/doi.org\/10.1007\/s00259-020-05126-w.","journal-title":"Eur J Nucl Med Mol Imaging."},{"issue":"9","key":"6327_CR62","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/s41571-019-0218-0","volume":"16","author":"F Martins","year":"2019","unstructured":"Martins F, Sofiya L, Sykiotis GP, Lamine F, Maillard M, Fraga M, et al. Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. Nat Rev Clin Oncol. 2019;16(9):563\u201380. https:\/\/doi.org\/10.1038\/s41571-019-0218-0.","journal-title":"Nat Rev Clin Oncol."},{"issue":"1","key":"6327_CR63","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1186\/s12885-021-08032-y","volume":"21","author":"S Dalle","year":"2021","unstructured":"Dalle S, Mortier L, Corrie P, Lotem M, Board R, Arance AM, et al. Long-term real-world experience with ipilimumab and non-ipilimumab therapies in advanced melanoma: the IMAGE study. BMC Cancer. 2021;21(1):642. https:\/\/doi.org\/10.1186\/s12885-021-08032-y.","journal-title":"BMC Cancer."},{"key":"6327_CR64","doi-asserted-by":"publisher","unstructured":"Vagenas TP, Economopoulos TL, Sachpekidis C, Dimitrakopoulou-Strauss A, Pan L, Provata A, Matsopoulos GK. A decision support system for the identification of metastases of Metastatic Melanoma using whole-body FDG PET\/CT images. IEEE J Biomed Health. Inform. 2022; https:\/\/doi.org\/10.1109\/JBHI.2022.3230060.","DOI":"10.1109\/JBHI.2022.3230060"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-023-06327-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-023-06327-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-023-06327-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T09:07:57Z","timestamp":1696324077000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-023-06327-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,15]]},"references-count":64,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["6327"],"URL":"https:\/\/doi.org\/10.1007\/s00259-023-06327-9","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,15]]},"assertion":[{"value":"7 February 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 June 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all participants enrolled in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Consent to publish has been received from all participants.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}